physiomics.co.uk/
@physiomics.bsky.social
Physiomics plc is a mathematical modelling company that combines cutting-edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma organisations streamline their drug development #PYC ( unofficial )
Looking forward to #BioForward2025! If you’re attending, we’d love to share how we use MIDD and Biometrics expertise to help #biotech & #pharma partners de-risk development, guide dose and schedule decisions & build confidence across the pipeline. Reach out to book a meeting #PYC
September 24, 2025 at 9:02 PM
Looking forward to #BioForward2025! If you’re attending, we’d love to share how we use MIDD and Biometrics expertise to help #biotech & #pharma partners de-risk development, guide dose and schedule decisions & build confidence across the pipeline. Reach out to book a meeting #PYC
Looking forward to a busy September for the @Physiomics team. We’ll be at #BioForward2025 in Oxford (30 Sept) and at Biomarkers & Precision Medicine UK in London (30 Sept–1 Oct), sharing how we help biotech & pharma de-risk drug development and advance #PrecisionMedicine. #PYC
September 24, 2025 at 9:01 PM
Looking forward to a busy September for the @Physiomics team. We’ll be at #BioForward2025 in Oxford (30 Sept) and at Biomarkers & Precision Medicine UK in London (30 Sept–1 Oct), sharing how we help biotech & pharma de-risk drug development and advance #PrecisionMedicine. #PYC
We’re heading to Colorado this Oct for #ACoP2025! Our team is looking forward to joining discussions on QSP, PBPK & Model-Informed Drug Development (#MIDD) – and sharing how we use these approaches to help drug developers make smarter, evidence-based decisions. @ISOP1 #PYC
September 11, 2025 at 4:44 AM
We’re in Birmingham for the UK Mathematical Biology Conference! ✨ Excited for talks on tumour modelling, treatment optimisation & how mathematical approaches drive smarter #drugdevelopment – themes that connect closely with the work we do at @Physiomics. #PYC
September 11, 2025 at 4:43 AM
We’re in Birmingham for the UK Mathematical Biology Conference! ✨ Excited for talks on tumour modelling, treatment optimisation & how mathematical approaches drive smarter #drugdevelopment – themes that connect closely with the work we do at @Physiomics. #PYC
Great to be at the first UK Mathematical Biology Conference in Birmingham.
From oncology & immunotherapies to bioinformatics & ML, it was a fantastic chance to see how modelling is shaping the future of #drugdevelopment.
Next up: #ACoP (18–21 Oct) & #BIOEurope (3–5 Nov)! 🙌
From oncology & immunotherapies to bioinformatics & ML, it was a fantastic chance to see how modelling is shaping the future of #drugdevelopment.
Next up: #ACoP (18–21 Oct) & #BIOEurope (3–5 Nov)! 🙌
September 11, 2025 at 4:43 AM
Great to be at the first UK Mathematical Biology Conference in Birmingham.
From oncology & immunotherapies to bioinformatics & ML, it was a fantastic chance to see how modelling is shaping the future of #drugdevelopment.
Next up: #ACoP (18–21 Oct) & #BIOEurope (3–5 Nov)! 🙌
From oncology & immunotherapies to bioinformatics & ML, it was a fantastic chance to see how modelling is shaping the future of #drugdevelopment.
Next up: #ACoP (18–21 Oct) & #BIOEurope (3–5 Nov)! 🙌
We're excited to attend the first UK Mathematical Biology Conference (4–5 Sept, @unibirmingham) 🗨️ Looking forward to discussions on mathematical oncology, optimising cancer treatment & modelling to enhance immunotherapies – all closely aligned with our work at @Physiomics. #PYC
August 13, 2025 at 9:41 PM
We're excited to attend the first UK Mathematical Biology Conference (4–5 Sept, @unibirmingham) 🗨️ Looking forward to discussions on mathematical oncology, optimising cancer treatment & modelling to enhance immunotherapies – all closely aligned with our work at @Physiomics. #PYC
📣 We're thrilled to announce that @Physiomics has secured two new contracts with a UK clinical-stage #biopharma company developing immunotherapies for a range of diseases. An exciting step forward as we officially launch our #Biometrics service line! physiomics.co.uk/new-head-of-bi…#PYCYC
https://physiomics.co.uk/new-head-of-bi…
July 20, 2025 at 7:45 PM
📣 We're thrilled to announce that @Physiomics has secured two new contracts with a UK clinical-stage #biopharma company developing immunotherapies for a range of diseases. An exciting step forward as we officially launch our #Biometrics service line! physiomics.co.uk/new-head-of-bi…#PYCYC
📣 We are very excited to announce our expanded partnership with DoseMe and the implementation of our Personalised Dosing Software onto their DoseMeRx platform. Read the full press release 👉 physiomics.co.uk/doseme-dosing-…#PYCY#PersonalisedDosingng @DoseMeApp
https://physiomics.co.uk/doseme-dosing-…
July 20, 2025 at 7:41 PM
📣 We are very excited to announce our expanded partnership with DoseMe and the implementation of our Personalised Dosing Software onto their DoseMeRx platform. Read the full press release 👉 physiomics.co.uk/doseme-dosing-…#PYCY#PersonalisedDosingng @DoseMeApp
📣 We’re excited to share that @Physiomics has exceeded market expectations for FY25. Key highlights include a successful launch of our Biometrics service line, new client diversification, and continued progress in personalised medicine. Read more: physiomics.co.uk/trading-update…#PYCYC
https://physiomics.co.uk/trading-update…
July 20, 2025 at 7:39 PM
📣 We’re excited to share that @Physiomics has exceeded market expectations for FY25. Key highlights include a successful launch of our Biometrics service line, new client diversification, and continued progress in personalised medicine. Read more: physiomics.co.uk/trading-update…#PYCYC
How can #MIDD help meet the #FDA’s dose optimisation expectations in #oncology?
In Part 2 of our series with Weatherden, we explore how MIDD supports smarter dosing decisions – from IND to Phase 2 & beyond.
Read the full article 👉physiomics.co.uk/dose-matters-n…
#biotech #pharma #PYC
In Part 2 of our series with Weatherden, we explore how MIDD supports smarter dosing decisions – from IND to Phase 2 & beyond.
Read the full article 👉physiomics.co.uk/dose-matters-n…
#biotech #pharma #PYC
June 14, 2025 at 6:11 AM
Next stop, Boston! ✈️ @Physiomics’ Hayley Close will be BIO International 2025 from 16–19 June. We’re excited to discuss how our expertise in quantitative pharmacology, MIDD, PK/PD, and QSP helps streamline #drugdevelopment and inform smarter decisions. #BIO2025 @IAmBiotech #PYC
June 14, 2025 at 6:10 AM
Next stop, Boston! ✈️ @Physiomics’ Hayley Close will be BIO International 2025 from 16–19 June. We’re excited to discuss how our expertise in quantitative pharmacology, MIDD, PK/PD, and QSP helps streamline #drugdevelopment and inform smarter decisions. #BIO2025 @IAmBiotech #PYC
We’re heading to BIO International 2025 in Boston (June 16-19)! Hayley Close is excited to discuss how our data-driven approach to #drugdevelopment can streamline smarter decisions across the R&D pipeline. Reach out to book a meeting at #BIO2025! #PYC #Biotech
May 30, 2025 at 4:56 AM
We’re heading to BIO International 2025 in Boston (June 16-19)! Hayley Close is excited to discuss how our data-driven approach to #drugdevelopment can streamline smarter decisions across the R&D pipeline. Reach out to book a meeting at #BIO2025! #PYC #Biotech
Day 1 at #ASCPT2025! Mark Davies and Hayley Close are ready to connect with leaders in clinical pharmacology and share how Physiomics' expertise in MIDD, PK/PD, and QSP can optimise drug development. Excited to talk smarter dosing, trial designs, and more! #PYC
May 30, 2025 at 4:55 AM
Day 1 at #ASCPT2025! Mark Davies and Hayley Close are ready to connect with leaders in clinical pharmacology and share how Physiomics' expertise in MIDD, PK/PD, and QSP can optimise drug development. Excited to talk smarter dosing, trial designs, and more! #PYC
We’re heading to #PAGE2025 in Thessaloniki next month! 🎉 Mark Davies & Lea Sta are looking forward to sharing how our expertise in #PKPD, #MIDD & model-based strategies helps de-risk and optimise #drugdevelopment. Planning to attend? Drop us a message – we’d love to meet. #PYC
May 12, 2025 at 6:16 AM
We’re heading to #PAGE2025 in Thessaloniki next month! 🎉 Mark Davies & Lea Sta are looking forward to sharing how our expertise in #PKPD, #MIDD & model-based strategies helps de-risk and optimise #drugdevelopment. Planning to attend? Drop us a message – we’d love to meet. #PYC
We’re heading to #ASCPT2025 in Washington DC, 28-30th May! 🌎 As specialists in #PKPD modelling, #QSP and biostatistics, we help pharma and biotech teams make smarter, faster development decisions. Come chat to our team to learn more - reach out to book a meeting! #PYC
May 12, 2025 at 6:15 AM
We’re heading to #ASCPT2025 in Washington DC, 28-30th May! 🌎 As specialists in #PKPD modelling, #QSP and biostatistics, we help pharma and biotech teams make smarter, faster development decisions. Come chat to our team to learn more - reach out to book a meeting! #PYC
The #FDA’s final guidance on dose optimisation is reshaping #oncology #drugdevelopment.
Catch up on Part 1 of our latest article with Weatherden, and stay tuned for Part 2 on the role of Model-Informed Drug Development (MIDD).
linkedin.com/pulse/dose-mat… #PYCY#Biotechc#Pharmama
Catch up on Part 1 of our latest article with Weatherden, and stay tuned for Part 2 on the role of Model-Informed Drug Development (MIDD).
linkedin.com/pulse/dose-mat… #PYCY#Biotechc#Pharmama
Discover thousands of collaborative articles on 2500+ skills
Discover 100 collaborative articles on domains such as Marketing, Public Administration, and Healthcare. Our expertly curated collection combines AI-generated content with insights and advice from ind...
https://linkedin.com/pulse/dose-mat…
May 12, 2025 at 6:15 AM
The #FDA’s final guidance on dose optimisation is reshaping #oncology #drugdevelopment.
Catch up on Part 1 of our latest article with Weatherden, and stay tuned for Part 2 on the role of Model-Informed Drug Development (MIDD).
linkedin.com/pulse/dose-mat… #PYCY#Biotechc#Pharmama
Catch up on Part 1 of our latest article with Weatherden, and stay tuned for Part 2 on the role of Model-Informed Drug Development (MIDD).
linkedin.com/pulse/dose-mat… #PYCY#Biotechc#Pharmama
x.com
March 2, 2025 at 5:22 PM
Congrats to our client Bicycle Therapeutics CEO Kevin Lee! He received @BIA_UK's prestigious Entrepreneur of the Year award for his outstanding leadership and impact in the UK life sciences sector. Very proud of Kevin’s role in shaping the future of #biotech #innovation. More here: bit.ly/4aEU8oO.
Kevin Lee, CEO of Bicycle Therapeutics, wins Entrepreneur of the Year at the 2025 BIA Gala Dinner
Kevin Lee, CEO of Bicycle Therapeutics, wins Entrepreneur of the Year at the 2025 BIA Gala Dinner
bit.ly
January 31, 2025 at 6:55 PM
Congrats to our client Bicycle Therapeutics CEO Kevin Lee! He received @BIA_UK's prestigious Entrepreneur of the Year award for his outstanding leadership and impact in the UK life sciences sector. Very proud of Kevin’s role in shaping the future of #biotech #innovation. More here: bit.ly/4aEU8oO.
2/2 💡 This study highlights how our PKPD-based modelling approach delivers data-driven insights, guiding clinical trial design and accelerating #oncology #drugdevelopment. Read the full article here 👇 nature.com/articles/s4141… @natureportfoli#OncologyResearchc#PYCYC
https://nature.com/articles/s4141…
January 31, 2025 at 1:16 PM
2/2 💡 This study highlights how our PKPD-based modelling approach delivers data-driven insights, guiding clinical trial design and accelerating #oncology #drugdevelopment. Read the full article here 👇 nature.com/articles/s4141… @natureportfoli#OncologyResearchc#PYCYC
1/2 📄 We're pleased to share our latest research with @merckgroup, now published in @BrJCancer. Our Virtual Tumour platform helps optimise combination therapies by modelling tumour growth inhibition (TGI) across different regimens. #PYC
January 31, 2025 at 1:16 PM
1/2 📄 We're pleased to share our latest research with @merckgroup, now published in @BrJCancer. Our Virtual Tumour platform helps optimise combination therapies by modelling tumour growth inhibition (TGI) across different regimens. #PYC
🙌 Day 1 of the 8th DDR Inhibitors Summit 💡 If you're attending, be sure to connect with our Head of Business Development, Hayley Close, to discuss how Physiomics plc uses PKPD/QSP based approaches to support your DDR #drugdiscovery and development efforts! #PYC
January 29, 2025 at 1:02 PM
🙌 Day 1 of the 8th DDR Inhibitors Summit 💡 If you're attending, be sure to connect with our Head of Business Development, Hayley Close, to discuss how Physiomics plc uses PKPD/QSP based approaches to support your DDR #drugdiscovery and development efforts! #PYC
Curious about how #MIDD can transform your #drugdevelopment journey? 🤔
MIDD leverages cutting-edge techniques like PK/PD and QSP to minimise risks & maximise insights – guiding decision-making & accelerating progress.
Learn how it can support your pipeline! ➡️
#PYC
MIDD leverages cutting-edge techniques like PK/PD and QSP to minimise risks & maximise insights – guiding decision-making & accelerating progress.
Learn how it can support your pipeline! ➡️
#PYC
January 29, 2025 at 11:36 AM
Curious about how #MIDD can transform your #drugdevelopment journey? 🤔
MIDD leverages cutting-edge techniques like PK/PD and QSP to minimise risks & maximise insights – guiding decision-making & accelerating progress.
Learn how it can support your pipeline! ➡️
#PYC
MIDD leverages cutting-edge techniques like PK/PD and QSP to minimise risks & maximise insights – guiding decision-making & accelerating progress.
Learn how it can support your pipeline! ➡️
#PYC
📄Curious to learn how modelling is advancing #drugdevelopment? Thrilled to share our collaborative research with @AstellasUS! Learn how our Virtual Tumour platform helped design a Phase 1 trial by optimising dosing for a novel immunotherapy combination: ascpt.onlinelibrary.wiley.com/doi/epdf/10.10…
https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.10…
January 28, 2025 at 12:30 PM
📄Curious to learn how modelling is advancing #drugdevelopment? Thrilled to share our collaborative research with @AstellasUS! Learn how our Virtual Tumour platform helped design a Phase 1 trial by optimising dosing for a novel immunotherapy combination: ascpt.onlinelibrary.wiley.com/doi/epdf/10.10…
We’re heading to Boston for the 8th Annual DDR Inhibitors Summit! ! ✈️ Connect with Hayley Close, our Head of Business Development, to learn how @Physiomics uses PKPD/QSP approaches to optimise dosing, refine combinations & accelerate drug discovery and development. 🧪 #PYC
January 28, 2025 at 11:40 AM
We’re heading to Boston for the 8th Annual DDR Inhibitors Summit! ! ✈️ Connect with Hayley Close, our Head of Business Development, to learn how @Physiomics uses PKPD/QSP approaches to optimise dosing, refine combinations & accelerate drug discovery and development. 🧪 #PYC